Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 276

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 276
---
 are limited, researchers believe about 110 of every 100,000 people age 30 to 64 years, or 
 about 200,000 Americans in total, have younger-onset dementia.                                                                  |

| ● | Someone in the US develops AD every 67 seconds and by 2050                           
 one new case of AD is expected to develop every 33 seconds (~1M new cases per year); |

| ● | Deaths due to Alzheimer’s disease between 2000 and 2019 
 have more than doubled, increasing 145%.                |

| ● | Among people aged 70, 61% of those with Alzheimer’s                                                   
 dementia are expected to die before age 80, compared with 30% of people without Alzheimer’s dementia. |

| ● | This results in a significant cost burden to families, and 
 payors such as Medicare and Medicaid:                      |

| ● | In 2025, total payments for all individuals with Alzheimer’s                                
 disease or other dementias are estimated at $384 billion (not including unpaid caregiving). |

| ● | Medicare and Medicaid are expected to cover $245 billion,                                                                          
 or 64%, of the total health care and long-term care payments for people with Alzheimer’s disease or other dementias. Out-of-pocket 
 spending is expected to be around $97B in 2025.                                                                                    |

| ● | Total payments for health care, long-term care and hospice                                                            
 care for people with Alzheimer’s disease and other dementias are projected to increase to nearly $1 trillion in 2050. |

The total lifetime cost of care for someone with dementia is estimated at $371,621. The figure below, adapted from the Alzheimer’s Association Report presents percentage changes in selected causes of death between 2000 and 2022 (all ages). While the proportion of deaths from heart disease, stroke, breast and prostate cancer, and HIV decreased, the proportion of deaths from AD in the US increased by over 140%. Percentage Changes in Selected Causes of Death (All Ages) in the US between 2000 and 2022 167 Over the past 20 years, several investigational drugs for AD failed in clinical development. These drugs were intended to affect different aspects of AD pathology. A fundamental challenge of AD is that at the point at which physicians can render a definitive diagnosis, the patient has already suffered massive neuronal loss leading to overt cognitive dysfunction. Thus, clinical trials that are conducted in patients with advanced disease at the time of their enrollment may